Navigation Links
Quintiles Data Management Surpasses 300 EDC Trials

Pacgen Biopharmaceuticals using innovative technology in study of

anti-infective drug

RESEARCH TRIANGLE PARK, N.C., March 5 /PRNewswire/ -- Quintiles Transnational Corp. today announced it has achieved another major milestone in the management of clinical trial data -- 300 clinical trials using Electronic Data Capture (EDC).

The milestone EDC trial is a Phase II study being conducted for Pacgen Biopharmaceuticals Corporation of Vancouver, British Columbia. Pacgen is studying an anti-infective drug for the treatment of oral candidiasis. Quintiles began using EDC in 1999 and has seen acceptance of the technology accelerate since then, with more than 94 EDC trials put into production in 2007.

"At Quintiles, EDC is quickly surpassing paper in the collection of clinical trial data as customers are placing increased value on our ability to give them expert guidance in the appropriate use of this technology, as well as the potential for savings in time and cost," said Paula Brown Stafford, Executive Vice President, Global Data Management and Biostatistics, and a member of the CDISC Board of Directors. "We have been able to demonstrate for the pharmaceutical and biotech industries that EDC, when used properly, can make much better use of available resources.

"With Pacgen, we're working with an emerging biopharmaceutical company that is conducting important research in infectious diseases," she added. "Quintiles looks forward to continuing to help Pacgen further develop its pipeline."

About Pacgen

Pacgen is a life sciences company focused on the development of therapeutics for the treatment of infectious and inflammatory diseases. The company's lead product, PAC-113, is an anti-fungal in a Phase II clinical program. Pacgen also has candidates in an early stage research program. The most advanced of these candidates is a novel peptide therapeutic, PAC-G31P, which is currently being investigated in preclinical studies for its potential to treat inflammatory diseases characterized by non-beneficial neutrophil recruitment and activation.

About Quintiles

Quintiles Transnational Corp. is powering the next generation of healthcare by providing a broad range of professional services in drug development, financial partnering and commercialization for the pharmaceutical, biotechnology and healthcare industries. With more than 19,000 employees and offices in more than 50 countries, it is focused on providing customer-centric solutions that are the gold standard of the industry. For more information, please visit the company's Web site at .

SOURCE Quintiles Transnational Corp.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Quintiles Central Laboratory in India Receives CAP Certification
2. Quintiles Transnational Forms New Ownership Team with Current Investors Gillings, TPG and Temasek Joined by Bain Capital and 3i
3. Quintiles Appoints John Goodacre as General Counsel
4. Quintiles Acquires Central American Research Organization
5. Biomoda, Inc. and Quintiles Announce Agreement for Regulatory Consulting
6. China Nepstar Chain Drugstore to Implement SAP ERP Solution to Optimize Management and Cost Controls and Enhance Operating Efficiencies
7. Standard Management Seeks Additional Shares
8. In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike
9. Pain Management For Your Pets, Key Information Every Pet Owner Should Know - Live Webcast to Pet Owners, March 13, 8:00 p.m. to 9:00 p.m. (EDT) Via Morris Animal Foundation
10. Pain Management For Pets, Key Strategies For Veterinarians - Live Webcast to Veterinarians, March 13, 7:00 p.m. to 8:00 p.m. (EDT) Via Morris Animal Foundation
11. Smith & Nephew Orthopaedic Reconstruction Global Management Team Announced
Post Your Comments:
(Date:11/25/2015)... Rouge, LA (PRWEB) , ... November 25, 2015 , ... ... in the United States District Court of Connecticut on behalf of a home health ... behalf of all current or former home health care workers employed by Humana, Inc., ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... is encouraging people across the country to celebrate their sobriety and show through ... to post “before and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on ...
(Date:11/25/2015)... Florida (PRWEB) , ... November 25, 2015 , ... ... testing for physicians and athletic programs, launches new Wimbledon Athletics Facebook ... of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is pleased to ... facial wrinkling. While many patients are aware of the benefits of Botox® in the ... to those suffering with discomfort, soreness, and pain as a result of Jaw Tension, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Research and Markets ( ) has announced the ... to 2020" report to their offering. ... the total market share in 2014. The market for ... to growth at the highest CAGR between 2015 and ... fast growing water, industrial gas treatment, pharmaceutical, and food ...
(Date:11/24/2015)... DELHI , November 25, 2015 ... invoked due to repeated failure of IVF cycles. After ... Bhatia was totally dejected and had lost all hopes that she would be ... first Indian miracle child conceived after failure of over ... to abroad (UK) before they decided to take one last attempt ...
(Date:11/24/2015)... Nov. 24, 2015  Natera, Inc. (Nasdaq: ... genetic testing and the analysis of circulating ... present at the 27 th  Annual Piper ... 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, Ph.D., CEO of ... business activities and financial outlook. ...
Breaking Medicine Technology: